CAS 475479-34-6|Aleglitazar
| Common Name | Aleglitazar | ||
|---|---|---|---|
| CAS Number | 475479-34-6 | Molecular Weight | 437.50800 |
| Density | 1.29 | Boiling Point | 665.151ºC at 760 mmHg |
| Molecular Formula | C24H23NO5S | Melting Point | / |
| MSDS | / | Flash Point | 356.071ºC |
Names
| Name | (2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]propanoic acid |
|---|---|
| Synonym | More Synonyms |
Aleglitazar BiologicalActivity
| Description | Aleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM.IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ)Target: PPARα/γAleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones. |
|---|---|
| Related Catalog | Research Areas >>Metabolic Disease |
| Target | PPARγ:19 nM (IC50) PPARα:38 nM (IC50) |
| References | [1]. Bénardeau A, Verry P, Atzpodien EA, et al. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat. Diabetes Obes Metab. 2013 Feb;15(2):164-74. [2]. Younk LM, Uhl L, Davis SN. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):753-63. [3]. Foley-Comer AJ, Young AM, Russell-Yarde F, et al. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. Expert Opin Investig Drugs. 2011 Jan;20(1):3-12. [4]. Cavender MA, Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. [5]. Bénardeau A, Benz J, Binggeli A, et al. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg Med Chem Lett. 2009 May 1;19(9):2468-73. |
Chemical & Physical Properties
| Density | 1.29 |
|---|---|
| Boiling Point | 665.151ºC at 760 mmHg |
| Molecular Formula | C24H23NO5S |
| Molecular Weight | 437.50800 |
| Flash Point | 356.071ºC |
| Exact Mass | 437.13000 |
| PSA | 110.03000 |
| LogP | 5.12830 |
| Index of Refraction | 1.627 |
| InChIKey | DAYKLWSKQJBGCS-NRFANRHFSA-N |
| SMILES | COC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O |
| Storage condition | 2-8℃ |
Synonyms
| UNII-41T4OAG59U |
| R-1439 |
| Aleglitazar |
